{"id":"W1551938148","doi":"10.1158/1538-7445.sabcs14-p5-19-09","title":"Abstract P5-19-09: Preliminary results from a phase 2 single-arm study of enzalutamide, an androgen receptor (AR) inhibitor, in advanced AR+ triple-negative breast cancer (TNBC)","year":2015,"lang":"en","type":"article","venue":"Cancer Research","topic":"Medical Imaging Techniques and Applications","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"Sunnybrook Health Science Centre","funders":"","keywords":"Enzalutamide; Medicine; Triple-negative breast cancer; Clinical endpoint; Tolerability; Androgen receptor; Oncology; Internal medicine; Response Evaluation Criteria in Solid Tumors; Phases of clinical research; Population; Breast cancer; Bicalutamide; Progesterone receptor; Progressive disease; Cancer; Estrogen receptor; Prostate cancer; Clinical trial; Adverse effect; Disease","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001566579,0.001643102,0.001668088,0.000336676,0.0003587806,0.00100119,0.0008095248,0.001100521,0.005527655],"category_scores_gemma":[0.0009691049,0.0004136993,0.001040953,0.0002929692,0.0006442352,0.0008154282,0.0002987846,0.002528498,0.00120088],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007372519,"about_ca_system_score_gemma":0.001417351,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001205777,"about_ca_topic_score_gemma":0.005321407,"domain_scores_codex":[0.9996432,0.0001679098,0.00002100391,0.00005862626,0.00004310385,0.00006615144],"domain_scores_gemma":[0.9993956,0.000130188,0.00008171106,0.00003437611,0.00004913666,0.0003090618],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5533339,0.09888604,0.00788615,0.001988784,0.003157778,0.001039576,0.0004138546,0.005026462,0.1071158,0.0006010021,0.0241892,0.1963615],"study_design_scores_gemma":[0.4747449,0.4880145,0.01822709,0.00008100554,0.000952538,0.0007374481,0.00009042131,0.002316901,0.005576745,0.0004866682,0.008714296,0.00005765029],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9737688,0.004308209,0.001955868,0.001603787,0.0002890802,0.004831541,0.007221436,0.0003842308,0.005637014],"genre_scores_gemma":[0.9665521,0.004008186,0.004689677,0.002952138,0.0003330579,0.003633187,0.01043207,0.000122388,0.007277224],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.005527655,"threshold_uncertainty_score":0.0184918,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1647467235936916,"score_gpt":0.4742801947823902,"score_spread":0.3095334711886986,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}